Business Context and Reporting Period
Company: RedHill Biopharma Ltd.
Filing Type: Form 20-F (Annual Report)
Period Ended: December 31, 2014
Accounting Standards: International Financial Reporting Standards (IFRS)
Business Overview: RedHill is an emerging Israeli biopharmaceutical company focused on developing and acquiring late clinical-stage, orally-administered drugs for inflammatory and gastrointestinal diseases. The company has no approved products for commercial sale and relies on licensing agreements and capital raises to fund operations.
Key Financial Metrics (Year Ended Dec 31, 2014)
| Metric | 2014 (USD '000s) | 2013 (USD '000s) |
|---|---|---|
| Total Revenues | 7,014 | 12 |
| Cost of Revenue | (1,050) | - |
| Research & Development Expenses | (12,700) | (8,100) |
| General & Administrative Expenses | (4,011) | (2,684) |
| Operating Loss | (10,647) | (10,772) |
| Net Loss (Comprehensive Loss) | (10,711) | (10,628) |
| Cash and Short-Term Investments | 22,945 | 12,113 |
| Working Capital | 24,299 | 10,186 |
| Total Assets | 28,856 | 14,340 |
| Total Liabilities | 3,845 | 2,415 |
| Accumulated Deficit | (42,218) | (33,260) |
| Loss Per Share (Basic) | $0.12 | $0.17 |
Material Changes vs. Prior Period
- Revenue Surge: Revenues increased from $12,000 in 2013 to $7.0 million in 2014. This was driven by a $7.0 million upfront payment received from Salix Pharmaceuticals for the exclusive worldwide license of RHB-106 (a bowel preparation product).
- Cost of Revenue: A cost of revenue of $1.05 million was recorded in 2014, primarily due to a royalty payment to Giaconda Limited triggered by the Salix transaction. No cost of revenue was recorded in 2013.
- R&D Expenses: Increased by 57% (from $8.1 million to $12.7 million), driven by approximately $3.5 million in clinical trial costs for RHB-104, RHB-105, and BEKINDA.
- G&A Expenses: Increased by 48% (from $2.7 million to $4.0 million) due to higher payroll, share-based payments, and professional services.
- Liquidity: Cash and short-term investments nearly doubled from $12.1 million to $22.9 million, bolstered by private placements in early 2014 and the Salix upfront payment.
Guidance, Outlook, and Risks
Outlook and Capital Needs: The company states that its current cash position is insufficient to complete the research and development of all therapeutic candidates. It expects to incur additional losses in the future and will need to raise substantial additional capital through equity or debt financing, or through commercialization agreements. The company does not anticipate paying cash dividends.
Key Pipeline Updates:
- RHB-105 (H. Pylori): Phase III trial ongoing; top-line data expected Q2 2015. Granted Qualified Infectious Disease Product (QIDP) designation.
- RHB-104 (Crohn's Disease): Phase III trial ongoing in North America and Israel.
- BEKINDA (Oncology/Gastroenteritis): Marketing Authorization Application (MAA) filed in Europe for oncology support; Phase III trial for gastroenteritis ongoing.
- RIZAPORT (Migraine): Received a Complete Response Letter (CRL) from the FDA regarding CMC issues; European MAA under review.
Material Risks:
- Regulatory Approval: Failure to obtain FDA or foreign regulatory approvals for any therapeutic candidate would prevent commercialization.
- Clinical Trial Uncertainty: Clinical trials are expensive and have uncertain outcomes; negative results could halt development.
- Third-Party Reliance: The company relies on third parties for manufacturing and clinical trials. Supply chain issues (e.g., raw material compliance for RIZAPORT) could cause delays.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional political and military instability.
- PFIC Status: The company may be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which could result in adverse tax consequences for U.S. investors.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $22.9 million cash balance against the projected burn rate for ongoing Phase III trials (RHB-104, RHB-105, BEKINDA).
- RIZAPORT Regulatory Status: Confirm the resolution of the FDA's Complete Response Letter regarding Chemistry, Manufacturing, and Controls (CMC) and the status of the European MAA.
- Salix Transaction Milestones: Monitor the achievement of the remaining $5 million in milestone payments and royalty triggers from the Salix Pharmaceuticals license.
- Manufacturing Compliance: Review updates on the raw material supplier compliance issues affecting RIZAPORT production.
- Share Dilution: Assess the impact of outstanding warrants (approx. 4.2 million ordinary shares and 358k ADSs) and options (approx. 18.3 million ordinary shares) on future equity dilution.